Coherus Oncology, Inc. (CHRS) Revenue History
Annual and quarterly revenue from 2013 to 2024
Compound Annual Growth Rate (CAGR)
Loading revenue history...
Revenue Growth Metrics
Revenue Breakdown (FY 2024)
CHRS's revenue distribution by segment and geography for fiscal year 2024
By Product/Segment
By Geography
CHRS Revenue Analysis (2013–2024)
As of March 1, 2026, Coherus Oncology, Inc. (CHRS) generated trailing twelve-month (TTM) revenue of $83.6 million, reflecting significant decline in growth of -83.7% year-over-year. The most recent quarter (Q3 2025) recorded $11.6 million in revenue, up 12.8% sequentially.
Looking at the longer-term picture, CHRS's 5-year compound annual growth rate (CAGR) stands at -5.6%, indicating revenue contraction over this period. The company achieved its highest annual revenue of $475.8 million in 2020.
Revenue diversification analysis shows CHRS's business is primarily driven by Product (97%), and Product and Service, Other (3%). With over half of revenue concentrated in Product, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including INCY (+21.2% YoY), GMAB (+21.0% YoY), and EXEL (+9.9% YoY), CHRS has underperformed the peer group in terms of revenue growth. Compare CHRS vs INCY →
Peer Comparison
Compare CHRS's revenue metrics with industry peers
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| CHRSCurrent | $84M | -83.7% | -5.6% | -41.8% | |
| INCY | $5.1B | +21.2% | +14.0% | 26.1% | |
| GMAB | $21.5B | +21.0% | +32.0% | 31.1% | |
| EXEL | $2.3B | +9.9% | +18.6% | 37.6% | |
| IBRX | $15M | +1026.0% | +221.4% | -2334.2% | |
| MRUS | $35M | +55.9% | +4.7% | -753.0% |
Historical Revenue Data
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $267.0M | +3.8% | $149.4M | 56.0% | $-111,667,000 | -41.8% |
| 2023 | $257.2M | +21.9% | $98.3M | 38.2% | $-203,199,000 | -79.0% |
| 2022 | $211.0M | -35.4% | $141.0M | 66.8% | $-256,880,000 | -121.7% |
| 2021 | $326.6M | -31.4% | $269.0M | 82.4% | $-263,858,000 | -80.8% |
| 2020 | $475.8M | +33.6% | $438.2M | 92.1% | $156.3M | 32.9% |
| 2019 | $356.1M | +22783.7% | $339.0M | 95.2% | $107.8M | 30.3% |
| 2018 | $1.6M | +0.0% | $-1,679,000 | -107.9% | $-204,416,000 | -13137.3% |
| 2017 | $1.6M | -99.2% | $-158,975,000 | -10216.9% | $-232,136,000 | -14918.8% |
| 2016 | $190.1M | +532.8% | $-64,334,000 | -33.8% | $-115,931,000 | -61.0% |
| 2015 | $30.0M | -3.4% | $-182,639,000 | -608.0% | $-219,067,000 | -729.2% |
See CHRS's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs CHRS Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare CHRS vs AGIO
See how CHRS stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is CHRS's revenue growth accelerating or slowing?
CHRS revenue declined -83.7% year-over-year, contrasting with the 5-year CAGR of -5.6%. TTM revenue fell to $84M. This reverses the prior growth trend.
What is CHRS's long-term revenue growth rate?
Coherus Oncology, Inc.'s 5-year revenue CAGR of -5.6% reflects the variable expansion pattern. Current YoY growth of -83.7% is below this long-term average.
How is CHRS's revenue distributed by segment?
CHRS reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2013-2024 are available for download. Segment mix reveals concentration and diversification trends.